
May 7 (Reuters) - Ipsen SA IPN.PA:
LATE-BREAKING EXPLORATORY DATA HIGHLIGHTS THE IMPACT OF IQIRVO® (ELAFIBRANOR) ON FATIGUE AND PROVIDES MECHANISTIC INSIGHTS INTO ANTI-INFLAMMATORY AND SYMPTOM-RELATED EFFECTS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS
IQIRVO DUAL PPARΑ/Δ ACTIVATION IMPACTS INFLAMMATION AND FIBROSIS
PPARΑ ACTIVATION LINKED TO FATIGUE IMPROVEMENT IN PRIMARY BILIARY CHOLANGITIS